4 / 58
% OS OS
Study
nº pts Loc Adv X+Gem Gem p
Gem+/-5FU bolus
(Berlin,2002)
362 10%
6,7m 5,4m 0,09
Gem+/-5FU/Lv
(Riess, 2005)
466 5,9m 6,2m 0,68
Gem +/-Capec.
(Hermann,2005)
319 21% 8,4m 7,3m 0,31
Gem+/-Capec.
(Cunningham,2009)
533 30% 7,1m 6,2m 0,08
Gem+/-Cisplat.
(Heinemann, 2003)
190 21% 7,5m 6 m 0,12
Gem+/-Oxaliplat.
(Louvet, 2004)
313 31%
9 m 7,1m 0,13
Gem+/-Oxaliplat. (
Poplin,ASCO-06)
576
10%
5.9m 4,9m 0,16
Gem+/-Cisplat.
(Colucci, 2010)
400 16% 7,2m 8,3m NS
Gem+/Marimasmat
(Bramhall,02)
239 28% 5,5m 5,5m 0,95
Gem+/-Tifarbinib
(Van Cutsem,04)
688 24% 6,4m 6,1m 0,75
Gem+/-Exatecan
(O´Reilly,2004)
349 21% 6,7m 6,2m 0,52
Gem+/-CPT-11
(Rocha-Lima, 2004)
360 14% 6,3m 6,6m 0,79
Gem+/-Pemetrexed
(Richards, 04)
565 9% 6,2m 6,3m 0,68
Gem+/-Cetuxi
(Philip, ASCO-07 )
735 21% 6,4m 5,9m 0,14
Gem+/-Beva
(Kindler, ASCO-07)
602 16% 5,8m 6,1m 0,78
Gem-Erlo+/-Beva
(Vervenne,ASCO-08)
607 15% 7,1m 6m 0,2
Gem+/- Axitinib
(Kindler, JCO 2011)
632 18% 8,5m 8,3m 0,5
Gem+/- Erlotinib
(Moore, 2007)
569 24%
6,2m 5,9m 0,02
Advanced pancreatic cancer
Phase III Gem vs Gem+2nd drug